The DOI matches its Crossref record.
Smoking and Alzheimer's Disease: A Review of the Epidemiological Evidence
Abstract
Overall evidence from 19 case-control studies of Alzheimer's disease (AD) and smoking shows a highly significant (p < 0.001) negative association [ever/never smokers, relative risk (RR) 0.64, 95% confidence interval (CI) 0.54-0.76]. Some studies have apparent design faults but the association is clearly evident in those which do not (RR 0.60, 95% CI 0.46-0.78). A report of a positive relationship from a prospective study can be dismissed due to unreliability of AD diagnosis on death certificates, and other study weaknesses. Although more data are needed on dose response and to rule out possible confounding, the negative association is consistent with other data suggesting nicotine protects against AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Nicotinic acetylcholine involvement in cognitive function in animals
Levin, E. D., & Simon, B. B. (1998) · Psychopharmacology · doi:10.1007/s002130050667 · Cited by 678
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
The Effects of Tobacco Smoke and Nicotine on Cognition and the Brain
Swan, G. E., & Lessov-Schlaggar, C. N. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9035-9 · Cited by 580
Ott, A., Slooter, A., Hofman, A., van Harskamp, F., Witteman, J., Van Broeckhoven, C., van Duijn, C., & Breteler, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07541-7 · Cited by 535
Epidemiology of Dementia and Alzheimer's Disease
Hendrie, H. C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00002 · Cited by 412
Effects of nicotinic stimulation on cognitive performance
Newhouse, P. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.11.001 · Cited by 405
Cataldo, J. K., Prochaska, J. J., & Glantz, S. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1240 · Cited by 335
Muscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity
Kalamida, D., Poulas, K., Avramopoulou, V., Fostieri, E., Lagoumintzis, G., Lazaridis, K., Sideri, A., Zouridakis, M., & Tzartos, S. J. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05935.x · Cited by 333
The role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 324
Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets
Lloyd, G. K., & Williams, M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35314-5 · Cited by 313
Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. L. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772808 · Cited by 285
Newhouse, P. A., Potter, A., & Levin, E. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711030-00005 · Cited by 267
Potential occupational risks for neurodegenerative diseases
Park, R. M., Schulte, P. A., Bowman, J. D., Walker, J. T., Bondy, S. C., Yost, M. G., Touchstone, J. A., & Dosemeci, M. (2005) · American Journal of Industrial Medicine · doi:10.1002/ajim.20178 · Cited by 256
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Court, J. A., Lloyd, S., Thomas, N., Piggott, M. A., Marshall, E. F., Morris, C. M., Lamb, H., Perry, R. H., Johnson, M., & Perry, E. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00088-8 · Cited by 135
A 2‐year follow‐up study of cigarette smoking and risk of dementia
Juan, D., Zhou, D. H. D., Li, J., Wang, J. Y. J., Gao, C., & Chen, M. (2004) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00779.x · Cited by 118
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Wang, H.-X., Fratiglioni, L., Frisoni, G. B., Viitanen, M., & Winblad, B. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009864 · Cited by 110
The Effect of Apolipoprotein E ε4 in the Relationships of Smoking and Drinking to Cognitive Function
Carmelli, D., Swan, G. E., Reed, T., Schellenberg, G., & Christian, J. C. (1999) · Neuroepidemiology · doi:10.1159/000026204 · Cited by 77
Smoking and Cognitive Impairment: A Population‐Based Study
Ford, A. B., Mefrouche, Z., Friedland, R. P., & Debanne, S. M. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01858.x · Cited by 50
Acetylcholinesterase inhibitors may improve myelin integrity
Bartzokis, G. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.020 · Cited by 41
A unifying hypothesis of alzheimer’s disease: III—Risk factors
Heininger, K. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(200001)15:1<1::aid-hup153>3.0.co;2-1
Metadata
- Authors
- Lee, P. N.
- Venue
- Neuroepidemiology
- Publisher
- S. Karger AG
- Published
- 1994
- Volume
- 13
- Issue
- 4
- Pages
- 131-144
- ISSN
- 0251-5350 (ISSN-L)
- 1423-0208
- OpenAlex
- W2094321474
- Cited by
- 206
- References
- 0
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.